# Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

> **NCT04982445** · PHASE4 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 44 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CABENUVA

## Key facts

- **NCT ID:** NCT04982445
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982445, "Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04982445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*